Philippe Jean-Pierre

---

• Type de publi. : Article dans une revue
• Date de publi. : 04/07/2025
• Auteurs : Zacharie Barrou DumontSimon GascoinJordi IngladaAndreas DietzJonas KöhlerMatthieu LafaysseDiego MonteiroCarlo CarmagnolaArthur BayleJean-Pierre DedieuOlivier HagolleP. Choler
• Organismes : Centre d'études spatiales de la biosphère Centre d'études spatiales de la biosphère Centre d'études spatiales de la biosphère Centre National d'Études Spatiales [Toulouse] University Hospital Leipzig = Universitätsklinikum Leipzig Eidgenössische Technische Hochschule - Swiss Federal Institute of Technology [Zürich] Centre d'Etudes de la Neige Centre d'Etudes de la Neige ABEST Horizons Centre d'Etudes de la Neige Laboratoire d'Ecologie Alpine Institut d'Asie Orientale Centre d'études spatiales de la biosphère Centre National d'Études Spatiales [Toulouse] Laboratoire d'Ecologie Alpine
• Publié dans The Cryosphere le 28/10/2020

---

Résumé : Abstract. Information on the spatial–temporal variability of seasonal snow cover duration over long time periods is critical for studying the responses of mountain ecosystems to climate change. However, this information is often lacking due to the sparse distribution of in situ observations or the lack of adequate remote sensing products. Here, we combined snow cover data from 10 different optical platforms, i.e. SPOT (Satellites Pour l'Observation de la Terre) 1–5, Landsat 5–8, and Sentinel-2A and Sentinel-2B, to build a time series of the annual snow melt-out day (SMOD, i.e. the first day of no snow cover) at 20 m resolution across the French Alps and Pyrenees (43 × 103 km2). We evaluated the pixel-wise accuracy of the computed SMOD using in situ snow measurements at 276 stations. We found that the residuals are unbiased (median error of 1 d) despite a dispersion (RMSE of 28 d), which suggests that this dataset can be used to study SMOD trends after spatial aggregation. We found average reductions of 21.4 d (5.78 d per decade) over the French Alps and 16 d (4.33 d per decade) over the Pyrenees over the period 1986–2023. The SMOD reduction is robust and significant in most parts of the French Alps and can reach 1 month above 3000 m. The trends are less consistent and more spatially variable in the Pyrenees. This dataset is available for future studies of mountain ecosystem changes and is updated every year using Sentinel-2 data.

---

Fichiers liés : tc-19-2407-2025.pdf

---

Source

---

• Type de publi. : Pré-publication, Document de travail
• Date de publi. : 04/07/2025
• Auteurs : Nicolas BarbierPierre PlotonHadrien TuletGaëlle ViennoisHugo LeblancBenoit BurbanMaxime Réjou-MéchainPhilippe VerleyJames BallDenis FeurerGrégoire Vincent
• Organismes : Botanique et Modélisation de l'Architecture des Plantes et des Végétations Botanique et Modélisation de l'Architecture des Plantes et des Végétations Botanique et Modélisation de l'Architecture des Plantes et des Végétations Botanique et Modélisation de l'Architecture des Plantes et des Végétations Botanique et Modélisation de l'Architecture des Plantes et des Végétations Université de Yaoundé I Ecologie des forêts de Guyane Botanique et Modélisation de l'Architecture des Plantes et des Végétations Botanique et Modélisation de l'Architecture des Plantes et des Végétations Botanique et Modélisation de l'Architecture des Plantes et des Végétations Laboratoire d'étude des Interactions Sol - Agrosystème - Hydrosystème Botanique et Modélisation de l'Architecture des Plantes et des Végétations

---

Résumé : This study benefited from an "Investissement d'Avenir" grant managed by the Agence Nationale de la Recherche (CEBA, ref. ANR-10-LABX-25-01), via project PHENOBS. We also acknowledge the support of the UE Biodiversa+ BiodivMon program (Project Coforfunc). We are thankful to Ilona Clocher, Jean-Louis Smock, Jean-Yves Goret, Florian Jeanne and Julien Engel for their help with drone data acquisition and/or processing. Access to the Paracou site and infrastructure (https://paracou.cirad.fr) was granted by CIRAD/Ecofog, and we thank Géraldine Derroire and all Phenobs project participants. We are grateful to Raphaël Pélissier for helping in the initial shaping of the Phenobs project and for his continued support.

---

Fichiers liés : 2025.06.27.661894.full_bioarXiv.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/07/2025
• Auteurs : Benoit YouSebastien CouraudPhilippe CeruseLionel BadetPhilippe PaparelAlice DurandMarielle GuilletPhilippe MerleGaelle LescuyerCharles-André PhilipFrancois DucrayMathieu PiocheLionel KarlinJean-Christophe LifanteOlivier GlehenPierre-Adrien BolzeMarion ChauvenetCarole Langlois-JacquesFabien SubtilMarie PiecykAurore CarrotDominique JoubertAlexandre PrieurBerengere VireSara CalattiniLea Payen
• Organismes : Institut de Cancérologie des Hospices Civils de Lyon Centre pour l'innovation en cancérologie de Lyon Institut de Cancérologie des Hospices Civils de Lyon Centre pour l'innovation en cancérologie de Lyon Institut de Cancérologie des Hospices Civils de Lyon Centre pour l'innovation en cancérologie de Lyon Institut de Cancérologie des Hospices Civils de Lyon Hôpital Edouard Herriot [CHU - HCL] Institut de Cancérologie des Hospices Civils de Lyon Institut de Cancérologie des Hospices Civils de Lyon Hôpital Edouard Herriot [CHU - HCL] Institut de Cancérologie des Hospices Civils de Lyon Hôpital Edouard Herriot [CHU - HCL] Institut de Cancérologie des Hospices Civils de Lyon Hôpital Edouard Herriot [CHU - HCL] Institut de Cancérologie des Hospices Civils de Lyon Centre pour l'innovation en cancérologie de Lyon Institut de Cancérologie des Hospices Civils de Lyon Hôpital Femme Mère Enfant [CHU - HCL] Institut de Cancérologie des Hospices Civils de Lyon Institut de Cancérologie des Hospices Civils de Lyon Hôpital Edouard Herriot [CHU - HCL] Institut de Cancérologie des Hospices Civils de Lyon Centre Hospitalier Lyon Sud [CHU - HCL] Research on Healthcare Performance Institut de Cancérologie des Hospices Civils de Lyon Institut de Cancérologie des Hospices Civils de Lyon Centre Hospitalier Lyon Sud [CHU - HCL] Institut de Cancérologie des Hospices Civils de Lyon Institut de Cancérologie des Hospices Civils de Lyon Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 Hospices Civils de Lyon Service de Biostatistiques [Lyon] Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 Service de Biostatistiques [Lyon] Hospices Civils de Lyon Institut de Cancérologie des Hospices Civils de Lyon Hospices Civils de Lyon Institut de Cancérologie des Hospices Civils de Lyon Institut de Cancérologie des Hospices Civils de Lyon Institut de Cancérologie des Hospices Civils de Lyon Centre pour l'innovation en cancérologie de Lyon Laboratoire de Biologie Médicale MultiSites [Bron]
• Publié dans Biomarker Research le 25/10/2020

---

Résumé : Abstract Background hPG 80 (circulating progastrin), initially recognized for its oncogenic properties due to its direct link to the Wnt signaling pathway, is secreted by cancer cells and detectable in the blood of cancer patients. The ONCOPRO centralized case-control study (NCT03787056) was designed to prospectively evaluate the diagnostic utility of hPG 80 in patients with 16 different types of cancer. Methods hPG 80 levels were measured in 421 patients with 16 newly diagnosed cancers (median age 65.6 years old) using the DxPG80.Lab kit (Biodena Care). The diagnostic performance of hPG 80 (the primary endpoint) was assessed by comparing baseline hPG 80 levels in cancer patients with those of 330 asymptomatic aged-matched healthy subjects from the general population. Results Between 2018 and 2022, a total of 506 cancer patients were enrolled in the study, with 421 assessable across 16 distinct cancer cohorts. hPG 80 concentrations were significantly higher in cancer patients compared to the healthy population (median 3.8 [IQR: 1.0-11.1] vs. 1.9 [IQR: 0.6–4.2] pM, P < 0.0001). hPG80 levels were not impacted by renal failure, liver dysfunction, or cancer-associated inflammation. The diagnostic accuracy in cancer patients was ROC AUC 0.63, 95% CI = [0.59–0.67]. The highest diagnostic accuracy was seen in patients with lung cancer (AUC 0.75, 95% CI [0.68–0.82]; specificity = 88% for hPG 80 > 7.73 pM in patients aged > 58 years old) and hepatocellular carcinoma HCC (ROC AUC 0.75, 95% CI [0.66-083]; specificity = 88% for hPG 80 > 7.73 pM in patients aged > 58 years old). Conclusions This large prospective study confirms that cancer patients have significantly higher hPG 80 blood concentration compared to the healthy population. Incorporating this straightforward ELISA assay into screening programs is warranted. Trial registration NCT03787056.

---

Fichiers liés : 40364_2025_Article_793.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/07/2025
• Auteurs : Fawzi KerkouriRomain EschalierSamir FarehChristelle MarquiéMina Ait SaidWalid AmaraFrédéric AnselmeMarc BadozNathalie BeharPierre BordacharRim El BouazzaouiLaure Champ RigotMichel ChauvinPhilippe ChevalierAntoine da CostaPascal DefayeJean Claude DeharoLaurent FauchierEstelle GandjbakhchEdouard GitenayJean-Baptiste GourraudCharles GuenanciaMaxime de GuillebonBenoît Guy-MoyatAlexis HermidaJérôme HourdainPeggy JaconPierre KhattarMikael LaredoLaurence JeselNicolas LelloucheChristophe LeclercqVincent MansouratiPhilippe MauryPierre MondolyJean-Luc PasquiéMichaël PeyrolBertrand PierreSylvain PlouxCharlotte PotelleNicolas SadoulJean Marc SellalEmilie VarletRodrigue GarciaVincent ProbstSerge BovedaEloi Marijon
• Organismes : Centre Hospitalier Régional Universitaire de Brest Optimisation des régulations physiologiques Service de cardiologie [CHU HEGP] Paris-Centre de Recherche Cardiovasculaire CHU Clermont-Ferrand Hôpital de la Croix-Rousse [CHU - HCL] Centre Hospitalier Régional Universitaire [CHU Lille] Hôpital Privé Jacques Cartier [Massy] Groupe Hospitalier Intercommunal Le Raincy-Montfermeil Service de Cardiologie [CHU Rouen] Service de cardiologie [CHRU de Besançon] Service de cardiologie et maladies vasculaires [Rennes] = Cardiac, Thoracic, and Vascular Surgery [Rennes] Département de cardiologie Centre Hospitalier Libourne Service de cardiologie et de pathologie vasculaire [CHU Caen] Clinique de l'Orangerie [Strasbourg] Services de Pneumologie, Exploration Fonctionnelle Respiratoire et Cardiologie Service de Cardiologie [CHU Saint-Etienne] Département de cardiologie [CHU de Grenoble] Département de Cardiologie [Hôpital de la Timone - APHM] Centre Hospitalier Régional Universitaire de Tours Institut de cardiologie [CHU Pitié-Salpêtrière] Departement de Cardiologie [Hôpital Saint-Joseph - Marseille] Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Service de Cardiologie [CHU de Dijon] Centre hospitalier de Pau Service de cardiologie [CHU Limoges] Cardiologie [CHU Amiens] Périnatalité et Risques Toxiques - UMR INERIS_I 1 UPJV Département de Cardiologie [Hôpital de la Timone - APHM] Département de cardiologie [CHU de Grenoble] Groupe Hospitalier Bretagne Sud Institut de cardiologie [CHU Pitié-Salpêtrière] Centre Hospitalier Universitaire [Strasbourg] Service de Cardiologie [Henri Mondor] Service de cardiologie et maladies vasculaires [Rennes] = Cardiac, Thoracic, and Vascular Surgery [Rennes] Centre Hospitalier Régional Universitaire de Brest Optimisation des régulations physiologiques Service Cardiologie [CHU Toulouse] Service Cardiologie [CHU Toulouse] Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] Centre Hospitalier Régional Universitaire [Montpellier] Service de cardiologie [Hôpital Nord - APHM] Centre Hospitalier Régional Universitaire de Tours Département de cardiologie Centre Hospitalier Régional Universitaire [CHU Lille] Service de Cardiologie [CHRU Nancy] Service de Cardiologie [CHRU Nancy] Service de cardiologie [CHU HEGP] Service de cardiologie [CHU de Poitiers] Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Clinique Pasteur [Toulouse] Service de cardiologie [CHU HEGP]
• Publié dans Journal of the American College of Cardiology le 26/10/2020

---

Résumé : Background: Defibrillation testing (DT) remains recommended during subcutaneous implantable cardioverter defibrillator (S-ICD) implantation due to limited supporting evidence. Objectives: The objective of this study was to evaluate the long-term impact of DT during S-ICD implantation. Methods: The HONEST (coHOrte fraNcaise des dEfibrillateurs Sous cuTanés) study is a nationwide, ongoing observational study, including all S-ICD recipients in France (2012-2019). Five-year endpoints were centrally adjudicated, and propensity score-weighted analyses compared outcomes by DT status. Results: Among 4,924 patients, DT was performed in 4,066 (82.6%), decreasing from 85.4% (2012-2014) to 66.9% in 2019 (P < 0.001). Nontested patients were older (51.2 vs 49.6 years; P = 0.007), had lower left ventricular ejection fraction (37.6% vs 43.3%; P < 0.001), and were more frequently implanted for primary prevention (68.0% vs 62.4%; P = 0.002) and structural heart disease (84.9% vs 76.8%; P < 0.001). DT-related complications occurred in 0.1%, including 2 deaths. Failure rate was 1.0%, with 87.8% undergoing corrective reinterventions. Independent predictors of DT failure were elevated shock impedance (≥89 Ω; OR: 4.60; 95% CI: 2.32-9.66; P < 0.001) and obesity (body mass index ≥30 kg/m2; OR: 2.17; 95% CI: 1.01-4.55; P = 0.007). After adjustment, DT omission was not associated with increased risks of overall mortality (HR: 1.17; 95% CI: 0.86-1.61; P = 0.313), cardiovascular mortality (HR: 1.04; 95% CI: 0.70-1.56; P = 0.846), sudden cardiac death (HR: 0.27; 95% CI: 0.04-1.72; P = 0.167), and appropriate (HR: 1.01; 95% CI: 0.78-1.30; P = 0.945) or inappropriate shocks (HR: 0.98; 95% CI: 0.78-1.23; P = 0.865). Combined rates of ineffective shocks or undetected ventricular arrhythmias were similar (0.05 vs 0.06 per 100 person-years). Conclusions: Our findings suggest that DT can be safely omitted in the majority of S-ICD recipients, whereas selective DT may be considered in higher-risk subgroups. (S-ICD French Cohort Study (HONEST); NCT05302115).

---

Fichiers liés : 2025 Kerkouri et al., Defibrillation Testing.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/07/2025
• Auteurs : Maxence JamesJacques TrouverieBenoit BernayAnne MarmagneFabien ChardonMarin-Pierre GéminPhilippe EtienneCéline Masclaux‐daubresse
• Organismes : Université de Caen Normandie Ecophysiologie Végétale, Agronomie et Nutritions NCS Institut Jean-Pierre Bourgin - Sciences du végétal Institut Jean-Pierre Bourgin - Sciences du végétal Ecophysiologie Végétale, Agronomie et Nutritions NCS Université de Caen Normandie Institut Jean-Pierre Bourgin - Sciences du végétal
• Publié dans The Plant Journal le 26/10/2020

---

Résumé :

---

Fichiers liés : 2025 - James - V‐ATPases and amino acid catabolism are strongly disturbed in the roots of autophagy.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/07/2025
• Auteurs : Anna Maria AuxiliaEmilie OliéJonathan DuboisEnrico CapuzziValérie AubinBruno AouizerateFrank BellivierRaoul BelzeauxCaroline DubertretDominique JanuelEmmanuel HaffenAntoine LefrereAgnès PelletierMircea PolosanRoman ReyP. RouxLudovic SamalinRaymund SchwanMichel WalterAntoine YrondiPierre-Michel LlorcaMarion LeboyerB EtainPhilippe Courtet
• Organismes : Département de Psychiatrie adulte [Hôpital de la Colombière - CHU Montpellier] Fondation FondaMental [Créteil] Institut de Génomique Fonctionnelle Département de Psychiatrie adulte [Hôpital de la Colombière - CHU Montpellier] Institut de Génomique Fonctionnelle Département de Psychiatrie adulte [Hôpital de la Colombière - CHU Montpellier] Fondazione IRCCS San Gerardo dei Tintori [Monza, Italy] Fondation FondaMental [Créteil] Centre Hospitalier Princesse Grace Centre hospitalier Charles Perrens [Bordeaux] Nutrition et Neurobiologie intégrée Fondation FondaMental [Créteil] Optimisation thérapeutique en Neuropsychopharmacologie Fondation FondaMental [Créteil] Hôpital Lariboisière-Fernand-Widal [APHP] Département de Psychiatrie adulte [Hôpital de la Colombière - CHU Montpellier] Fondation FondaMental [Créteil] Hôpital Louis Mourier - AP-HP [Colombes] Institut de psychiatrie et neurosciences de Paris Fondation FondaMental [Créteil] Fondation FondaMental [Créteil] Centre de Recherche Clinique [Neuilly-sur-Marne] Centre d'Investigation Clinique de Besançon Fondation FondaMental [Créteil] Laboratoire de recherches Intégratives en Neurosciences et psychologie Cognitive Assistance Publique - Hôpitaux de Marseille Institut de Neurosciences de la Timone Fondation FondaMental [Créteil] Institut Mondor de Recherche Biomédicale CHU Henri Mondor [Créteil] Fondation FondaMental [Créteil] Fédération Hospitalo-Universitaire de Médecine de Précision en Psychiatrie = Addiction And Psychiatry Transformation with Precision Medicine [Créteil, France] Centre Hospitalier Universitaire [CHU Grenoble] Fondation FondaMental [Créteil] [GIN] Grenoble Institut des Neurosciences Fondation FondaMental [Créteil] Centre Hospitalier le Vinatier [Bron] Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center Fondation FondaMental [Créteil] Centre de recherche en épidémiologie et santé des populations Centre Hospitalier de Versailles André Mignot Fondation FondaMental [Créteil] Institut Pascal CHU Clermont-Ferrand Fondation FondaMental [Créteil] Centre Psychothérapique de Nancy [Laxou] Université de Lorraine Hopital de Bohars - CHRU Brest Fondation FondaMental [Créteil] Centre Hospitalier Universitaire de Toulouse Fondation FondaMental [Créteil] Toulouse NeuroImaging Center Fondation FondaMental [Créteil] CHU Clermont-Ferrand Institut Pascal Fondation FondaMental [Créteil] CHU Henri Mondor [Créteil] Fédération Hospitalo-Universitaire de Médecine de Précision en Psychiatrie = Addiction And Psychiatry Transformation with Precision Medicine [Créteil, France] Institut Mondor de Recherche Biomédicale Optimisation thérapeutique en Neuropsychopharmacologie GHU AP-HP Nord - Université Paris Cité Fondation FondaMental [Créteil] Fondation FondaMental [Créteil] Département de Psychiatrie adulte [Hôpital de la Colombière - CHU Montpellier] Institut de Génomique Fonctionnelle
• Publié dans European Psychiatry le 23/10/2020

---

Résumé : Introduction: Suicidal behaviors (SB) in bipolar disorder (BD) are major adverse outcomes that may influence disease progression. While staging models exist for psychiatric disorders, none include suicide. This study aims to stratify suicidal risk in BD, propose a staging model for SB, and assess its clinical utility. Methods: Participants from the FondaMental Advanced Center of Expertise for Bipolar Disorder (FACE-BD) cohort were categorised into five stages (St) based on SB: St0 (no suicidal ideation [SI]), St1 (SI but no suicide attempt [SA]), St2a (non-severe/violent SA), St2b (severe /violent SA), and St3 (multiple SAs). Stages were analysed based on demographic, clinical, cognitive, and biological characteristics using logistic regression. Results: Key differences emerged between stages. St1 showed longer untreated illness and higher lability and lower functioning than St0. St2a was linked to anxiety, substance use disorders, and longer disorder duration, while male gender and lithium bitherapy were protective. St2b exhibited shorter untreated illness and higher childhood trauma (CTQ) scores, with male gender and alcohol use as risk factors. St3 was associated with BD-II, alcohol use, longer disorder duration, and more depressive episodes, but less anxiety. No biochemical or cognitive differences were found across stages. The model was significantly associated with SA occurrence (LRT = 28.74, p < 0.0001). Conclusion: This staging model for suicidality in BD provides a multifaceted approach to risk stratification and predictive insights, although further refinement is needed.

---

Fichiers liés : Auxilia et al 2025.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/07/2025
• Auteurs : Adrien Ter SchiphorstPierre SenersAnke WoutersNicole YuenMichael MlynashJeremy HeitStephanie KempSøren ChristensenDenis SablotAnne WacongneThibault LaluAude PhilippeCaroline ArquizanVincent CostalatGregory W AlbersMaarten Lansberg
• Organismes : Département de Neurologie [Hôpital Gui de Chauliac - CHU Montpellier] Stanford Stroke Center Institut de psychiatrie et neurosciences de Paris Institut de psychiatrie et neurosciences de Paris Stanford Stroke Center Hôpital Fondation Adolphe de Rothschild = Adolphe de Rothschild Foundation Hospital Catholic University of Leuven = Katholieke Universiteit Leuven Stanford Stroke Center Stanford Stroke Center Stanford University Stanford Stroke Center Stanford Stroke Center Centre Hospitalier Saint Jean de Perpignan Centre Hospitalier Universitaire de Nîmes Centre Hospitalier de Béziers Centre Hospitalier Régional Universitaire [Montpellier] Hôpital Gui de Chauliac [CHU Montpellier] Institut de psychiatrie et neurosciences de Paris Département de Neuroradiologie [CHRU Montpellier] Institut de psychiatrie et neurosciences de Paris Stanford Stroke Center Stanford Stroke Center
• Publié dans Stroke le 31/10/2020

---

Résumé : Background: For patients with acute ischemic stroke due to a large vessel occlusion admitted in primary stroke centers, helicopter transfer to comprehensive stroke centers is often used to expedite access to mechanical thrombectomy. Some studies have suggested that vibrations generated during helicopter transport might enhance intravenous thrombolysis (IVT) efficacy. We aimed to evaluate the impact of helicopter transfer, compared with ground transportation, on interhospital recanalization and functional outcomes. Methods: We conducted a retrospective analysis of 2 prospectively collected cohorts of anterior circulation acute ischemic stroke due to a large vessel occlusion patients transferred to 2 comprehensive stroke centers (Stanford, CA, November 2019 to January 2023, and Montpellier, France, January 2015 to January 2017) for mechanical thrombectomy consideration with arterial imaging both at the primary stroke center and on comprehensive stroke center arrival. The primary outcome was interhospital recanalization, determined by comparison of the baseline and posttransfer arterial imaging and defined as revised arterial occlusive lesion scores of 2b to 3. The association between transportation mode (helicopter versus ground) and interhospital recanalization was studied in logistic regression analysis, adjusting for pretransfer IVT use, occlusion site, and transfer duration. Results: Among 520 included patients, 315 (61%) were transferred by helicopter and 259 (50%) received IVT before transfer. Interhospital recanalization rates were similar between helicopter and ground transfers in both the overall cohort (23% versus 19%; P=0.30) and the IVT subgroup (36% versus 33%; P=0.61). Adjusted analyses confirmed no association between helicopter transport and interhospital recanalization (adjusted odds ratio, 1.23 [95% CI, 0.72-2.11]; P=0.44). Favorable 3-month functional outcome (modified Rankin Scale score, 0-2) rates were also similar between helicopter and ground transfers in both unadjusted (35% versus 40%; P=0.29) and adjusted analyses (adjusted odds ratio, 1.12 [95% CI, 0.67-1.88]; P=0.67). Conclusions: In this multicenter observational cohort study, helicopter transfer was not associated with improved interhospital recanalization or favorable functional outcomes compared with ground transport. These findings do not support the hypothesis that vibrations during helicopter transport enhance IVT efficacy.

---

Fichiers liés : Ter Schiphorst Stroke 2025.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/07/2025
• Auteurs : Grace AdwaneMaarten LansbergSimon LiebartFrederique CharbonneauMaya SchwartzJeremy HeitMichael MlynashDenis SablotAnne WacongneJean-Philippe DesillesVincent CostalatMichael ObadiaCarole HenryEric ManchonCaroline ArquizanGregory AlbersAdrien ter SchiphorstPierre Seners
• Organismes : Hôpital Fondation Adolphe de Rothschild = Adolphe de Rothschild Foundation Hospital Stanford University Stanford Stroke Center Hôpital Gui de Chauliac [CHU Montpellier] Hôpital Fondation Adolphe de Rothschild = Adolphe de Rothschild Foundation Hospital Stanford University Stanford University Stanford University Centre Hospitalier Saint Jean de Perpignan Centre Hospitalier Universitaire de Nîmes Optimisation thérapeutique en Neuropsychopharmacologie Hôpital Fondation Adolphe de Rothschild = Adolphe de Rothschild Foundation Hospital French-Clinical Research Infrastructure Network - F-CRIN [Lille] FHU NeuroVasc [Site Sainte-Anne, Paris] Département de Neuroradiologie [CHRU Montpellier] Hôpital Fondation Adolphe de Rothschild = Adolphe de Rothschild Foundation Hospital Centre Hospitalier de Saint-Denis [Ile-de-France] Centre Hospitalier de Gonesse Hôpital Gui de Chauliac [CHU Montpellier] Institut de psychiatrie et neurosciences de Paris Stanford University Institut de psychiatrie et neurosciences de Paris Hôpital Gui de Chauliac [CHU Montpellier] Stanford University Hôpital Fondation Adolphe de Rothschild = Adolphe de Rothschild Foundation Hospital Stanford Stroke Center Institut de psychiatrie et neurosciences de Paris
• Publié dans International Journal of Stroke le 31/10/2020

---

Résumé : Background: Patients with acute ischemic stroke and a large vessel occlusion admitted to non-endovascular capable centers frequently require inter-hospital transfer to a comprehensive stroke center (CSC) for thrombectomy. Data regarding arterial recanalization of patients with basilar artery occlusion (BAO) during transfer are lacking. Methods: We analyzed prospectively collected data of acute stroke patients with BAO transferred for consideration of thrombectomy to three CSCs (Rothschild Hospital, France; Montpellier Hospital, France; Stanford Hospital, USA) between 2016 and 2024, with arterial imaging at the referring hospital and on CSC arrival. Inter-hospital recanalization was assessed by comparison of the baseline and post-transfer arterial imaging and was defined as 2a-3 on the modified Thrombolysis In Cerebral Infarction (mTICI) scale. Independent predictors of inter-hospital recanalization were assessed using multivariable logistic regression analysis. Results: Overall, 228 patients were included: median age 71 years, the National Institutes of Health Stroke Scale (NIHSS) of 14, transfer time of 3.5 h, and 39% of patients received intravenous thrombolysis (IVT) before transfer. The primary reason for withholding IVT was late presentation. Inter-hospital BAO recanalization occurred in 15% of patients. Variables independently associated with inter-hospital BAO recanalization were IVT use (adjusted odds ratio (aOR) = 24.3, 95% confidence interval (CI) = 6.9-85.5, P < 0.01), distal BAO site (aOR = 2.9, 1.0-8.5, P = 0.05), lack of diabetes (aOR = 11.4, 1.4-93.2, P = 0.02), and non-atheromatous etiology (aOR = 6.6, 1.4-31.4, P = 0.02). BAO recanalization rates ranged from 1% in non-IVT-treated patients with proximal BAO to 45% in IVT-treated patients with distal BAO. Inter-hospital recanalization was associated with an increased odds of good functional outcome (odds ratio (OR) for 3-month modified Rankin Scale (mRS) = 0-2 = 3.3, 95% CI = 1.2-8.8, P = 0.02, adjusted for age, pre-stroke mRS, baseline NIHSS, Posterior Circulation Alberta Stroke Program Early Computed Tomography Score (pc-ASPECTS), IVT use, and onset-to-imaging time). Conclusions: BAO recanalization during inter-hospital transfer for thrombectomy occurred in 15% of patients and was associated with a favorable 3-month outcome. IVT use in the referring center was the primary modifiable factor associated with recanalization, yet its use remains low. Expanding IVT indications in primary stroke centers and developing new therapies that increase recanalization may improve outcomes.

---

Fichiers liés : Adwane et al IJS 2025.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/07/2025
• Auteurs : Philippe RicaudPierre DurandPaolo GrigioniVirginia CiardiniMassimo del GuastaGiuseppe CamporealeJean-Luc AttiéEric Bazile
• Organismes : Centre national de recherches météorologiques Laboratoire d'aérologie Agenzia Nazionale per le nuove Tecnologie, l’energia e lo sviluppo economico sostenibile = Italian National Agency for New Technologies, Energy and Sustainable Economic Development Agenzia Nazionale per le nuove Tecnologie, l’energia e lo sviluppo economico sostenibile = Italian National Agency for New Technologies, Energy and Sustainable Economic Development Istituto Nazionale di Ottica [Firenze] Laboratoire d'aérologie Centre national de recherches météorologiques
• Publié dans Polar Science le 02/11/2020

---

Résumé : While the majority of Antarctic clouds are made up of ice crystals, a significant proportion consists of supercooled liquid water (SLW), defined as water in liquid form below 0 • C. Observations of SLW clouds have been carried out for several years at Dome C, the Concordia station (75 • S, 123 • E; 3233 m above mean sea level), combining observations from LIDAR, microwave radiometer and balloon-borne sondes. The present analysis is separated in two parts. Firstly, we will focus on the diurnal variation of the planetary boundary layer (PBL) from balloon-borne profile observations performed on January 23, 2023 establishing the presence of SLW clouds: 1) at the top of the PBL between the entrainment zone and the capping inversion layer, 2) higher up within a fossil layer, and 3) within the very cold stable boundary layer close to the surface as liquid fog. Secondly, from a statistical study covering several summer periods, we will show that SLW clouds are present from 400 to 600 m above ground level (agl) in the entrainment zone and within the stable boundary layer below 100 m agl where liquid fog can form, with temperatures from -25 • C to -35 • C and LWP (liquid water path, the vertically-integrated SLW content) less than 3.0 g m -2 .

---

Fichiers liés : 1-s2.0-S1873965225000933-main.pdf

---

Source

---

• Type de publi. : Communication dans un congrès
• Date de publi. : 30/06/2025
• Auteurs : Laurent MazenqPierre-François CalmonAdrian LabordeFranck CarcenacAurélie LecestreLudovic SalvagnacPascal DubreuilÉric ImbernonDavid BourrierHugues GranierLiviu NicuPhilippe MeniniGuilhem LarrieuPierre JosephMorgan Delarue
• Organismes : Service Techniques et Équipements Appliqués à la Microélectronique Service Techniques et Équipements Appliqués à la Microélectronique Service Techniques et Équipements Appliqués à la Microélectronique Service Techniques et Équipements Appliqués à la Microélectronique Service Techniques et Équipements Appliqués à la Microélectronique Service Techniques et Équipements Appliqués à la Microélectronique Service Techniques et Équipements Appliqués à la Microélectronique Service Techniques et Équipements Appliqués à la Microélectronique Service Techniques et Équipements Appliqués à la Microélectronique Service Techniques et Équipements Appliqués à la Microélectronique Laboratoire d'analyse et d'architecture des systèmes Équipe MICrosystèmes d'Analyse Laboratoire d'analyse et d'architecture des systèmes Équipe Micro-Nanofluidique pour les sciences de la vie et de l’environnement Équipe Micro-Nanofluidique pour les sciences de la vie et de l’environnement

---

Résumé : This presentation will show how established micro- and nanofabrication techniques contribute to progress in electronics, sensing technologies, and medical applications. After introducing the cleanroom environment, essential for controlling contamination and ensuring high-precision fabrication, it will highlight versatile processes for creating thin films, patterning materials, and defining structures at micro- and nanoscales. The talk will showcase advanced lithography and etching techniques that enable the miniaturization of components, unlocking new possibilities for high-performance devices. Examples of ongoing projects, such as the development of sensitive gas sensors for environmental and health applications, will illustrate the transition from fabrication processes to real-world solutions. Finally, an overview of current research will demonstrate how micro- and nanotechnologies are evolving to meet the demands of future applications, particularly in life sciences and cancer diagnostics, paving the way for smarter, more efficient, and more integrated devices.

---

Source